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Background. Multiple national organizations and leaders have called for increased attention to dementia 
prevention in those most vulnerable, for example persons with limited formal education.  Prevention 
recommendations have included calls for multicomponent interventions that have the potential to improve both 
underlying neurobiological health and the ability to function despite neurobiological pathology, or what has 
been termed cognitive reserve.   
Objectives. Test feasibility, treatment modifier, mechanism, and cognitive function effects of a multicomponent 
intervention consisting of foods high in polyphenols (i.e., MIND foods) to target neurobiological health, and 
speed of processing training to enhance cognitive reserve.  We refer to this multicomponent intervention as 
MINDSpeed. 
Design. MINDSpeed is being evaluated in a 2x2 randomized factorial design with 180 participants residing 
independently in a large Midwestern city.  Qualifying participants are 60 years of age or older with no evidence 
of dementia, and who have completed 12 years or less of education.  All participants receive a study-issued 
iPad to access the custom study application that enables participants, depending on randomization, to select 
either control or MIND food, and to play online cognitive games, either speed of processing or control games.    
Methods. All participants complete informed consent and baseline assessment, including urine and blood 
samples.  Additionally, up to 90 participants will complete neuroimaging.  Assessments are repeated 
immediately following 12 weeks of active intervention, and at 24 weeks post-randomization.  The primary 
outcome is an executive cognitive composite score.  Secondary outcomes include oxidative stress, pro-
inflammatory cytokines, and neuroimaging-captured structural and functional metrics of the hippocampus and 
cortical brain regions.   
Summary. MINDSpeed is the first study to evaluate the multicomponent intervention of high polyphenol intake 
and speed of processing training.  It is also one of the first dementia prevention trials to target older adults with 














Testing dementia prevention interventions in high risk populations has been a recent research 
recommendation of multiple leading organization, including the National Academy of Medicine (NAM)1, the 
National Institutes of Health,2 3 and internationally recognized leaders.4-6  In fact, some of the world’s leading 
dementia scientists recommend a policy and research shift toward reducing risk and increasing reserve; neural 
or cognitive reserve is one’s ability to function despite pathology.5   
In Dementia Prevention—a call for contextualized evidence, Drs. Lafortune and Brayne highlight that “very 
limited evidence is available regarding effective dementia prevention for populations of low socioeconomic 
status (SES) and for minority or marginalized groups.”6  The NAM Cognitive Aging report recommended 
evaluation of multi-component cognitive interventions for vulnerable populations.  In the study described here, 
we seek to test an intervention involving two positive behaviors that may have additive effects on cognition—
consumption of high polyphenol foods and speed of processing training.  Diet addresses neurobiologic risk 
factors and indirectly addresses cognitive reserve, while cognitive training directly addresses cognitive reserve. 
Low education7 is the top population-attributable Alzheimer’s disease (AD) risk factor worldwide.8  Low 
cognitive reserve is a leading hypothesis for low education’s effects on early cognitive decline and AD onset.9  
Adult hippocampal neurogenesis (AHN) is fundamental to maintaining cognitive reserve10 and diet plays a 
critical role in maintaining an environment conducive to AHN.11  Unfortunately, low education is often 
associated with unhealthy dietary habits12 that are difficult to completely eliminate.13  However, supplementing 
unhealthy dietary habits with healthier foods has real potential to impact cognitive health and function.13  For 
example, moderate adherence to the “MIND” diet developed by the Rush Memory and Aging group cut AD risk 
by one-third over 4.5 years.14  The diet was built from epidemiological15,16 and randomized controlled trial 
evidence that consumption of certain foods can improve short-term cognition.17-19  Specifically, plant-based 
polyphenol compounds have emerged as key interventions for cognitive health and function.11,20   
While dietary components support the creation of new neurons, cognitive training promotes integration of 
neurons into neural networks.21-23  Speed of processing training, in particular, results in very large performance 
gains
24-26
 that have been maintained for years.
27,28
  “Speed training” targets fluid mental processing speed and 
reduces the length of time needed to process more and more complex information.29  In a secondary analysis 
of data from the largest cognitive training trial ever conducted, we showed speed training had a large effect 
among participants with fewer than 12 years of education; the effect size was 50% larger in those with fewer 
than 12 years of education compared to the subsample with 16 or more years and this difference was 
maintained to 5 year follow-up.30  
At this time, we are not aware of any published randomized trials of speed of processing training, i.e., Speed, 
combined with high polyphenol foods, i.e., MIND foods.  Nor are there published randomized trials of MIND 
foods or Speed training properly designed and powered to assess effects in older adults with low education.  













In a 2x2 factorial design, we are testing in a randomized controlled trial the effects of high polyphenol “MIND” 
foods and speed training (MINDSpeed) in older adults with low education (see Figure 1).  Support for the 
feasibility and efficacy of the MINDSpeed intervention could lead to a follow-on AD prevention trial through 
existing and scalable programs and applications such as home-delivered meal programs and home Internet.  
Figure 1. Study Design here 
The primary specific aim of this pilot clinical trial is to determine MINDSpeed effects on an executive cognitive 
composite score relative to control interventions.  The primary hypotheses are that MINDSpeed is more 
effective than MIND food or Speed training alone and all are more effective than control in improving the 
objective composite measure at immediate post-training (3 months post-randomization) and then at 3-months 
post-training (6 months post-randomization).   
Secondary aims are to determine: 1) feasibility (i.e., adherence, adverse events, costs), 2) treatment effect 
modifiers (e.g., education, age, baseline cognitive status, APOE ε4 carrier status), and 3) mechanisms 
including the roles of inflammation, oxidative stress, hippocampal and cortical volume, and functional 
connectivity.   
The MIND Food and Speed of Processing Training in Older Adults with Low Education Alzheimer's Disease 
Prevention Pilot Trial is funded by the National Institute on Aging (R01 AG052439).  The study is approved by 
the Indiana University Institutional Review Board and registered in clinicaltrials.gov (NCT 1703766063).   
Recruitment and Randomization Process 
Recruitment is a multi-step process in cooperation with Eskenazi Health.  Eskenazi is one of the five largest 
safety-net health systems in the United States and actively provides care to approximately 20,000 adults aged 
60 years or over.  First, health system data managers with access to the electronic medical record (EMR) will 
identify patients who meet study demographic and clinical criteria.  Second, providers will be alerted that their 
patient may be eligible, and given the opportunity to opt-out any patient from contact for potential participation.  
Third, potentially eligible participants will be approached at an Eskenazi federally qualified health center 
(FQHC) visit or called by telephone by a research assistant.  Those indicating interest will complete a brief 
screener followed by information about the study interventions and assessments.  Fourth, those who remain 
interested and eligible will schedule an appointment to complete informed consent and baseline assessment.  
Assessments will be completed at the Eskenazi Center for Brain Care Innovation and the IU Center for 
Neuroimaging by trained assessors.  Finally, participants completing all baseline assessments will be 
randomized.  Randomization will be stratified by age (60-69; 70 and over) and neuroimaging completion. 
Within each stratum, subjects will be randomized to one of the four training arms with random block sizes of 4 
and 8. The randomization list will be generated using computer software and placed in sealed envelopes that 
are consecutively numbered. Following completion of the baseline assessment, the research coordinator will 
open the next available envelope in the appropriate stratum to assign treatment.     
Those consented and randomized will receive a study provided iPad tablet running our MINDSpeed 
application.  The app will provide each participant with 12 weeks of access, support, and incentives for the 
interventions of the 4-arm randomized controlled trial: 1) MIND food + Speed training, 2) MIND food + Speed 
training control, 3) MIND food control + Speed training, or 4) MIND food control + Speed training control.   
Inclusion and Exclusion Criteria 
As noted, the target population is adults aged 60 years or over born in the United States who self-report 12 or 
fewer years of lifetime formal educational attainment.  Additional inclusion criteria are English speaking, native-
born U.S. resident living in Marion County, Indiana.  Exclusion criteria include EMR or self-reported diagnosis 
of dementia, Alzheimer disease (AD), multiple sclerosis, epilepsy, schizophrenia, bipolar disorder, Parkinson 
disease; cancer with short life expectancy or current cancer treatment; stroke or myocardial infarction within 
the past twelve months; brain tumor, brain surgery, or brain infection; current alcohol consumption ≥8 drinks 
per week for women or ≥15 drinks per week for men; self-reported poor vision (difficulty reading a newspaper) 












assessments; prior involvement in similar cognitive training studies; unwilling or unable to provide blood 
sample at baseline assessment. In addition, participants who complete optional neuroimaging will be 
withdrawn if baseline MRI shows clinical evidence of tumor, hemorrhage, aneurysm, or hydrocephalus.   
Interventions 
Active (i.e., MIND and Speed) and control interventions will be delivered through an app operating on study-
provided iPads.  In an effort to maximize uptake, adherence, and scalability, our professional design team 
worked with older less educated adults and consultants to create the interventions.  User-centered design and 
behavioral principles guided the intervention development.  In particular, design preferences were guided by 
two principles: 1) “easy” substantially increases uptake,31 and 2) small incentives as frequent and close in time 
to the behavior as possible significantly improve adherence.32,33 34   
Our UX design team led a user-centered design research effort to integrate the speed of processing and MIND 
food interventions.  First, five older adults evaluated application screens and functions rendered on Sketch 
(https://www.sketchapp.com/).  Second, these same users experienced tablet-operated, interactive prototypes 
created through an application called Axure (http://www.axure.com/).  Third, the design was evaluated by an 
outside expert team including human factors and software engineers and design researchers.  Finally, the 
MINDSpeed app was evaluated in a different group of five users for one week (ages 52-76yrs).  The pilot study 
involved a combination of interview sessions, iterative design and usability evaluation of the prototype, food 
delivery and reporting, and game play (BrainHQ) (see Figure 2 MINDSpeed – “Good Afternoon”).  Some older 
adults with low education have limited reading skills, low computer familiarity, and limited eyesight.  Thus, a 
major objective of the design work was to make the application easy for the target group to use.  This has been 
achieved.  First time users reported "this is self-explanatory" and "I will know how to use after first time, pretty 
simple."  Findings from the pilot indicated that participants shop through the app, received home delivered 
foods, played speed training games, and tracked incentives with ease and high satisfaction.  
Figure 2. MINDSpeed Home Page here 
The Speed Intervention arm. Speed of processing training will be provided by the Internet-based BrainHQ 
program from Posit Science, Inc.  BrainHQ contains five different speed training modules (Hawk Eye, Visual 
Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) that tap time-order judgment, visual discrimination, 
spatial-match, forward-span, instruction-following, and memory.35  The Posit program systematically reduces 
stimulus presentation time to maintain an 85% accuracy rate and launches each new session based on the 
stopping point of the preceding session.  Participants will receive performance ratings relative to their prior trial 
upon completion of each “exercise.”  Participants will be incentivized to train 100 minutes (minimum) per week 
for 12 weeks, which exceeds by 15 minutes the training in the successful Advanced Cognitive Training for 
Independent and Vital Elderly (ACTIVE) study.24,29  Participants will be encouraged to play 15 minutes per day, 
and 5¢ will be added to the incentive account for every minute of play up to $5 per week.  The cumulative 
incentive amount will be displayed at the top of the home screen in the app.  Through the Posit Science 
research platform, we will have real-time, objective records of training time per module, per session, for each 
participant. 
Figure 3. Food Ordering Screen here 
MIND foods Intervention arm. Participants randomized to the MIND food intervention arm will shop for and 
receive high polyphenol foods through the app (see Figure 3, “Order Food”).  The food component of the 
intervention is intended to replace some usual food items and thus is not intended to add additional calories to 
one’s diet.  Participants will select seven food items; one for each day of a week.  Servings of each item have 
been designed to provide a minimum of 1,000 mg of polyphenols with up to 500 mg coming from flavonoids, in 
particular flavanols, as determined from the Phenol-Explorer database.36,37  These minimum polyphenol levels 
were determined from existing evidence regarding mechanistic changes related to polyphenol levels.38,39  The 
food options within the app are restricted to those selected or created by our study nutrition scientists working 
with Eskenazi nutritionists.  Selected foods will be delivered to the participant’s place of residence once per 












prompted each day of the week to report whether the purchased food was consumed.  An incentive of $1 for 
each daily report will be added to the cumulative incentive total.   
The Control interventions are designed to mimic the activities of the MIND and Speed interventions.  The food 
control participants will experience all of the features of the MIND food participants with the exception that the 
foods available to order will be limited to whole foods very low in polyphenols (e.g., corn, rice, potatoes, 
iceberg lettuce, pears, etc).  Speed control participants will experience the same app features as Speed 
participants but in place of speed training will play control games on the iPad judged to be inert (e.g., War Ship, 
Bricks Squasher).  The control games were created by independent game developers, and the games are 
hosted by BrainHQ for research purposes.  All participants regardless of intervention type will be eligible for up 
to $12 per week of incentives (maximum of $7 for daily food reports and $5 for 100 minutes of game play). 
Intervention Maintenance.  After the 12-week post-training assessment, incentives and food allowances will 
cease but participants will have continued access to games on the project iPad.  Those in the MIND or 
MINDSpeed arm will receive recipes and ingredient lists and be encouraged to maintain MIND food 
consumption.  Maintenance was chosen over total cessation of the intervention because it holds potential to 
maximize treatment potency, provides information on the rates of self-managed adherence, which speaks to 
reach and effectiveness of the interventions, and may enhance subject retention to the 6-month follow-up.     
Intervention Fidelity.  Treatment fidelity and monitoring as defined by the NIH Behavior Change Consortium 
Strategies40 and checklist41 is enhanced by app-delivery and daily food and objective game data.  A help 
button on the MINDSpeed app allows participants to reach staff or request a call back (8 to 5, M-F).  All staff 
have personally played BrainHQ active and control games, and experienced the MIND foods and control 
foods.  Staff have quick access to our UX designer and programmer, as well as Posit Science technical 
support and our clinical nutritionists.  The intervention support staff and blinded assessor complete study 
training prior to working with enrolled subjects.   
Measures 
All assessments will be completed at the Eskenazi Center for Brain Care Innovation and the IU Health 
Neuroscience Center by trained, certified, and blinded assessors.  Unless otherwise noted, measures are 
taken at baseline (BL), immediate post-training (PT), and 6 month follow-up (FU).  Participants will indicate 
occurrence of leisure-time cognitive training, physical exercise, and formal educational activities.42  At each 
assessment, we will measure body weight and height.  Subjects will stand flat footed, shoes removed, in light 
clothing.  Blood pressure will be taken from the left arm using an automatic device after the participant has 
been resting 5 minutes in an upright, seated position.  For blood pressure, two separate measurements will be 
taken and averaged.    
Cognitive Status Determination.  We complete the Mini-mental State examination (MMSE) because it has: 1) 
been widely used as a global measure of cognitive status43, which facilitates the characterization of our sample 
to those of past studies, 2) excellent reliability and validity,44 and 3) modified scoring for low education 
samples.45  In scoring, both a traditional and education-modified score will be computed.   
Feasibility Outcome Measures.  We will track the number of potential participants approached, screened, and 
enrolled to gauge recruitment success using ≥ 50% of eligible participants enrolled as the criterion.  We will 
also monitor the safety, acceptability, and adherence of the app-delivered interventions and outcome 
measurements.  Safety will be assessed by comparing adverse event rates, both serious (i.e., hospitalizations) 
and non-serious (i.e., anxiety, allergy symptoms) across treatment groups.  The acceptability of the 
experimental and control interventions will be measured using weekly self-report survey asking of satisfaction 
(i.e., 1 = very satisfied, 3 = neutral, 5 = very dissatisfied) with scores from 1-2 indicating acceptability.  
Adherence will be documented by dates, episodes, and time spent in completing speed training modules and 
food reports.  Maintenance will be determined from training data and diet assessments (see below) at PT to 
FU.   
Cognitive Outcome Measures.  Consistent with the conceptual model, the primary outcome is a cognitive 
function composite.  Our executive cognitive composite consists of verbal fluency (Controlled Oral Word 
Association, 3-letter phonemic fluency; Category Fluency, 3-category semantic fluency),46 Symbol Search from 












in 45 seconds on the color-word trial)49 for each participant at each occasion of measurement.  Raw scores for 
each test are standardized using the baseline mean and standard deviation.  A composite is then formed as an 
average of z-scores.  In addition, List Learning from the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) will also be administered to assess new learning and memory.  
Diet Assessment.  At each assessment (BL, PT, and FU), participants will be asked to complete the VioScreen 
Food Frequency Questionnaire (FFQ), a validated web-based FFQ which allows for complex skip patterns, 
portion size estimation based on images, and real-time error checking.50  The FFQ will be interviewer-
administered and will provide an estimation of usual kilocalories, and macro- and micro-nutrients.50  In addition, 
we will use urine samples to obtain “biomarkers of compliance” as was done in the recently completed 
PREDIMED multisite RCT.51  We will use the “fast and simple” rapid Folin-Ciocalteu method to determine total 
polyphenols at BL, PT, and FU.52   
Self-reported Outcomes.  The Geriatric Depression Scale will measure depression,53 a modified Cognitive Self-
Report Questionnaire will measure cognition and engagement, and one question of the SF-3654 to measure 
self-reported health.  Instrumental activities of daily living will be measured by self-report using portions of 
Minimum Data Set-Home Care.24   
APOE Collection and Assay.  Genomic DNA will be extracted from blood samples using the DNeasy Blood & 
Tissue Kit (Qiagen, Inc., Valencia, CA) according to the manufacturer's protocol.  Approximately 50ng of 
genomic DNA will be used for amplification.  APOE genotypes will be determined by restriction enzyme 
digestion of amplified DNA.55 
Treatment and Adherence Modifiers. Individual difference factors with potential to modify response to 
treatment and adherence will be measured at BL including:  age, race, gender, years of education, APOE ε4 
allele status, baseline cognitive status (via the MMSE), height and weight to compute body mass index, blood 
pressure, Charlson Comorbidity Index,56 depression, self-reported visual acuity, and reading ability (via Wide 
Range Achievement Test-IV Reading).   
Blood Biomarkers.  Fasting blood samples will be obtained at BL, PT, and FU in all subjects to explore the 
mechanisms of action.  The conceptual model holds that the cognitive benefit of combined training is achieved 
through modulation of physiologic processes related to neural proliferation, oxidative balance, and metabolic 
function.  As a result, we will measure circulating levels of the pro-inflammatory cytokines IL-1α, IL-1β, IL-6, 
and TNF-α; the anti-inflammatory cytokines IL-1ra and IL-10; the acute-phase reactant C-reactive protein; 
vascular endothelial growth factor and brain derived neurotrophic factor; and also metabolic processes 
reflected in insulin resistance and blood glucose.  Oxidative stress will be determined from thiobarbituric acid 
reactive substances (TBARS), a byproduct of lipid peroxidation.  We will also measure plasma biomarkers for 
levels of amyloid-β as a predictor for amyloid-β deposition in the brain, which is the earliest pathological sign of 
Alzheimer’s disease.  We will obtain 4 ten ml purple top EDTA tubes of blood taken in the fasting state.  Blood 
samples will be centrifuged within 10 minutes of collection.  Plasma aliquots will be stored at -80°C until the 
time of assay.  Measures will be performed in the Analyte Lab at the Center for Diabetes and Metabolic 
Diseases at Indiana University (1P30DK097512 Mirmira R [PI]).  We will obtain a Paxgene RNA tube at these 
same 3 intervals and bank for future RNA-sequence analysis since the intervention may alter the transcriptome 
/ mRNA expression levels.  
Cost. We will track all personnel, equipment, technology, and support costs associated with delivering the 
interventions thus allowing an estimation of intervention costs on a per subject basis.   
MRI Acquisition Protocol. The following scans will be performed on a research-dedicated new generation 
Siemens Prisma 3T scanner with a 64CH receiver-only head coil: 1) Sagittal survey 3-plane localizer; 2) T1-
weighted Magnetization Prepared Rapid Acquisition Gradient Echo (MP-RAGE) 3D anatomical volume; 3) 
High resolution T2-weighted hippocampal sequence; 4) Axial T2-weighted Fluid-Attenuated Inversion 
Recovery (FLAIR) sequence; 5) Diffusion field map; (6) Diffusion tensor imaging (DTI); 7) EPI-Field map #1 
(anterior to posterior (AP)), 8) EPI-Field map #2 (posterior to anterior (PA)), and 9) Blood Oxygenation Level 
Dependent (BOLD) functional task-based MRI. The structural MP-RAGE and high-resolution hippocampal 
sequences will be collected following the Alzheimer’s Disease Neuroimaging Initiative protocols 
(http://adni.loni.usc.edu/methods/documents/mri-protocols/). The FLAIR parameters are as follows: Sagittal T2-












1800ms, iPAT factor = 2, scan time = 4:22. The DTI scan parameters are as follows: Axial SS-SE-EPI 
acquisition; b-value=1000s/mm2, 60 directions, 3 b0 images, 69 slices, voxel-size = 2mm x 2mm x 2mm, TR = 
2290ms, TE = 64.8ms, flip angle = 90, multi-band factor = 3, iPAT factor = 2, scan time = 2:56. The functional 
MRI task is Scene Encoding and Recognition, modified from Detre and colleagues,57-59 which elicits reliable 
bilateral medial temporal lobe activation. BOLD fMRI parameters are as follows: Axial GE-EPI acquisition, 54 
slices, voxel-size = 2.5mm x 2.5mm x 2.5mm, TR = 1200ms, TE = 29ms, flip angle = 65, multi-band factor = 3, 
scan time = 5:16. 
Safety.  We have standard regulatory reporting procedures in the Data and Safety Monitoring Plan (DSMP) 
and the operation of our Data Safety and Monitoring Board (DSMB).  Adverse events are documented by study 
staff and reviewed by the local safety officer and DSMB chair.  Cognitive training is relatively safe but anxiety 
and burden can occur and will be monitored.  Magnetic resonance imaging (MRI) is a safe procedure for 
people who do not have metal implants or other contraindications.  Study personnel will screen participants for 
these risk factors prior to enrollment.  Before entering the MRI environment, participants will be re-screened for 
MRI contraindications.  Physical confinement or noise in MRI can be uncomfortable, and all efforts will be 
made to assure participant’s comfort.  Blood draws and urine collections will be conducted by trained and 
certified Eskenazi clinical staff.  Finally, a small number of participants may develop depression, dementia, or 
physical dysfunction during the study.  Should this occur, we will direct the subject to appropriate clinical care 
(i.e., primary care provider or specialty clinic as needed).  
Sample Size and Power 
The primary analysis of the study focuses on the evaluation of the effectiveness of the interventions on the 
cognitive outcome, executive cognitive composite.  We therefore determined the sample size to ensure 
adequate power for this analysis.  In these prior studies, speed of processing training was found to have an 
effect size (ES) of 1.4 standard deviation (SD) at immediate post-training (PT) and 1.2 SD at one year PT on 
processing speed outcomes.24  MIND diet is a brain health optimized hybrid of the Mediterranean-DASH diets, 
and the latter were found to have an effect size of 0.44 to 0.56 SD on executive function and speed of 
processing.60  There are no published trials of speed of processing training combined with MIND diet but we 
expect a large effect size of the combined intervention.  With an overall alpha level of 0.05 for six Bonferroni-
adjusted two-sided comparisons, a conservative estimate of the correlation of 0.7 between baseline and follow-
up outcomes, and 15% estimated six month attrition rate taken from our prior geriatric intervention trial,61 the 
sample size of 45 subjects per treatment arm will yield 80% power to detect an effect size of 0.6 SD based on 
the constrained longitudinal data analysis (cLDA).62  The cLDA63 has been shown to produce greater efficiency 
and handle missing data more flexibly with valid inference when data are missing at random.62,64  Cognitive 
aging studies support an effect size of over one-half standard deviation as clinically meaningful.65-67 
Secondary Aims and Power: Secondary outcomes include inflammation, metabolic function, oxidative stress, 
and hippocampal and cortical structure and function (via MRI).  For non-imaging outcomes, we will have a full 
sample and adequate power to detect effect sizes of 0.6.  Imaging creates anxiety and discomfort for some, 
however.  Thus, in addition to using information and communication strategies shown to reduce imaging 
anxiety68 we will complete imaging on the minimum necessary.  From the literature, we anticipate large effect 
sizes on the brain outcomes of structure and function.  Cognitive training has resulted in changes in brain 
structure with approximate effect size of 0.56 in left hippocampus volume following spatial navigation training 
among healthy younger and older men69 and an approximate effect size of 0.47 in gray matter density (GMD) 
after the completion of a multi-domain computerized cognitive training among healthy older adults.22  In 
addition, our preliminary results showed an effect size of 0.5 in annual percent change in hippocampal volume 
and 0.8 in annual percent change in hippocampal GMD among older adults without MCI who are frequently 
engaged in reading and puzzle-solving compared to those who are not.  Food interventions alone have had an 
effect size of 0.7 on hippocampal volume.11,38  Other studies support effect sizes of 0.64 to above 1.00 on 
functional connectivity.70,71  A one-half subsample of each arm (n=22 per arm) with an alpha level of 0.05 and a 
correlation of 0.7 between baseline and post-training with 15% attrition provides 80% power to detect an effect 
size of 0.83 or larger for the brain imaging outcome. 
In order to test the mediating effect of blood biomarkers, brain structure, and brain function variables we need 
to establish the association between the mediating variable and primary outcome, after controlling for the 
intervention effect.  Such an association is evaluated using a partial correlation.  With our sample size, we 












variables and the primary memory composite outcome.  Evaluation of moderating effects is an exploratory aim 
and detection of such effects requires large sample sizes.  Our study is therefore only able to explore treatment 
moderators. In addition, our sample size of 45 subjects per arm provides accuracy with no more than 8% 
margin of error at the 95% confidence level for feasibility outcomes.     
Analyses 
Preliminary Analyses.  These analyses will include comparing baseline characteristics of participants across 
treatment arms.  We will also compare the baseline scores on outcome measures across treatment arms.  For 
continuous variables, means and standard deviations will be reported.  Frequency tables will be reported for 
categorical variables.  Normality of continuous outcomes will be examined using a normal probability plot.  For 
highly skewed measurements, appropriate transformations will be applied to achieve approximate normality.  
Repeated measurements over time will be graphed as spaghetti plots and examined for outliers.  All data will 
be examined for completeness.  The baseline characteristics will be compared across treatment arms and 
between participants who do and do not complete the study.  If any significant differences exist, we will control 
for differences in the subsequent analyses.  Analyses will be performed under the intention-to-treat paradigm. 
Primary Analysis.  The primary analysis of the intervention effect on executive cognitive composite will be 
performed using the constrained longitudinal data analysis (cLDA) proposed by Liang and Zeger.63 Repeatedly 
measured executive cognitive composite outcomes at BL, PT, and FU will be modeled as dependent variables 
with the baseline mean responses constrained to be the same across intervention arms due to randomization. 
This model is flexible in handling missing data and has been shown to provide greater power than other 
models when testing intervention effects and yields valid results when data are missing at random. The 
clustering effect of repeated measures within a subject will be accommodated using a random subject effect. 
Time of measurement (BL, PT, FU) and its interaction with intervention arm will be included in the model. The 
time of measurement is considered as a categorical variable to allow non-linear time effect. Intervention effects 
are captured by the significant interaction effect. Comparison of outcome measures across intervention arms at 
PT and FU will be estimated based on the model using appropriate contrasts.  In order to assess whether the 
intervention effect is affected by physical activity change, weight change, or other factor, we will examine 
change patterns across intervention arms. If the change pattern differs across intervention arms, that factor will 
be controlled by including its main effect and interaction with the intervention arm in the primary analysis for 
intervention effect on executive cognitive composite. 
Analysis of MRI scans.  Scans will be processed using standard techniques and normalized to standard space 
for analysis (i.e. Montreal Neurologic Institute, MNI). Structural MRI scans will be processed using voxel-based 
morphometry (VBM) in Structural Parametric Mapping (SPM12) and FreeSurfer (v6) as previously described.72-
75  High-resolution hippocampal scans will be processed to generate volumetric estimates of hippocampal 
subfields as described in previous work.76  DTI scans will be preprocessed as in 77 and 78, with eddy current 
and other corrections using FMRIB Software Library (FSL) 79 producing a single corrected image. DTI scalar 
measures, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity 
(RD) will be computed by using FSL. Using Camino, DWI voxel-wise data will be modeled by using zero 
(isotropic diffusion), one (one major gradient diffusion), or two tensors (crossing fibers) using cutting-edge 
techniques as in 80 and 81-83. Both streamline and probability tractography will be performed to generate specific 
white matter tracts and structural connectivity. A number of statistics (represented by structural connectivity 
(SC) matrices) will then be generated from the tractography data, including number of fibers, fiber density (as 
in 84), average length of the streamlines (in mm), and average fractional FA and minimum FA within and among 
the streamlines. Task-related fMRI scans will be processed using methods described our prior work.85,86 
Briefly, contrast images of task-related activation (scene presentation) relative to control conditions (scrambled 
scenes) will be generated using standard pre-processing techniques (i.e., slice time correction, normalization, 
etc.) implemented in SPM12.85,86 These contrast images (scene > control, control > scene) will be used for 
further analysis.  
Images will be compared between those receiving the combined intervention, a single intervention, and control 
cross-sectionally and longitudinally on voxel-wise and ROI levels. Cross-sectional voxel-wise analyses will 
compare the scans between groups at BL and PT. Longitudinal voxel-wise analysis will model time-by-group 
interactions using a two-way Analysis of Covariance (ANCOVA) model. All voxel-wise analyses will be 












preprocessed scans. Specifically, cross-sectional and longitudinal change in regional brain atrophy (i.e., MTL, 
frontal lobe, hippocampal subfields), white matter (WM) integrity (i.e., FA, MD from MTL tracts) and structural 
connectivity, and task-related fMRI activation will be compared between intervention groups over time. 
Secondary Analyses. Feasibility outcomes including intervention adherence, acceptability and rates of adverse 
events will be estimated using the 95% confidence intervals Self-reported outcomes including depression, 
cognition and engagement, quality of life, and IADL will be examined using the cLDA methods described 
immediately above.   
Mechanism Analyses. Mechanistic hypotheses are that, relative to control at PT, intervention arm participants 
will have greater hippocampal and cortical volume, better metabolic function, higher levels of neurotrophic 
growth factors, and lower levels of inflammation and oxidative stress.  Hypotheses will be analyzed using 
cLDA.  With regard to MRI, scan analysis described immediately above will be performed on targeted pre-
specified ROIs and followed by spatially unbiased whole brain voxel-based analyses.  Supplemental analyses 
will compare across scan modalities to address the relative incremental contribution of each modality (e.g. 
hippocampal volume, cortical volume, WM integrity, etc.) to capturing the overall neuroimaging outcome. 
Moderator and Mediator Analyses. Analyses will be performed to determine the role of adherence, years of 
education, age, baseline cognitive scores, comorbidity, and APOE ε4 carrier status (an indicator of elevated 
ADRD risk) in moderating intervention outcomes using cLDA.  We hypothesize in particular that participants 
with greater adherence, less education, and lower comorbidity will experience larger executive cognitive 
composite score gains.  A three-way interaction between potential moderators, intervention arm, and time of 
measurement will be included in the model and a significant three-way interaction indicates the moderating 
effect.  To evaluate hypothesized mediators of the speed training and MIND foods (e.g., inflammation, growth 
factors, oxidative stress, hippocampal and cortical volume), we will use the approach proposed by Krull and 
Mackinnon (2011) 87 that allows the testing of mediating effects in clustered data.  Using the change in 
executive cognitive composite outcome from baseline as the dependent variable, a series of three mixed 
effects models will be fit and regression coefficients from these models will be used to estimate the direct and 
indirect treatment effects.  
The cLDA provides valid inference when data are missing due to random dropouts.  Sensitivity analyses will be 
performed to examine to what extent the results are affected when dropouts are not missing at random. 
Analyses based on complete cases, mean imputation, and worst case imputation will be performed.  In 
addition, missing data patterns will be examined and a pattern mixture model will be used to allow different 
intervention effects for subjects with different missing data patterns.  Results based on these models will be 
compared to results from cLDA. 
Discussion 
The MINDSpeed trial is among the first to test either high polyphenol foods or speed of processing training 
among older adults with low education, and as far as we know the first to test these interventions in 
combination in any group.  As such, the feasibility aims of this pilot trial are important.  The primary aim, to test 
the effect of these interventions on our objective executive cognitive composite score, is obviously key but the 
aims to test mechanisms and moderators of effects of these interventions in this high risk population are also 
of high significance.  Our conceptual model hypothesizing mechanisms through which these interventions 
could enhance cognitive reserve and sustain or improve cognition is well supported by recent theoretical and 
empirical literature but much investigation is yet needed.  Principally, whether making room in one’s usual diet 
for foods that achieve high polyphenol intake (e.g., >1,000mg per day) is sufficient to meaningfully reduce 
inflammation, oxidative stress, insulin resistance, and neurodegeneration.  Similarly, whether speed of 
processing training increases growth factors, neurogenesis, and brain structure and function.  Our investigation 
of moderators is more exploratory in nature, but includes factors, such as age, education, or APOE ε4 carrier 
status, that may be critical to future tailoring or intervention targeting. 
Combinatorial interventions for preventing or delaying ADRD have been a recommendation of multiple national 
organizations and scientific leaders.  With few such interventions to date, we believe it is critical to evaluate the 
feasibility of combinatorial interventions in populations at high risk for ADRD such as older adults with low 












treatment and assessment adherence.  If adherence via the MINDSpeed app drops below 80%, we will 
institute, first, increased incentives and, second, telephone reminder and support calls.  Study retention is also 
a feasibility challenge.  With fair subject payments in past work, we have completed one-half day assessments 
that include imaging at the Indiana University Center for Neuroimaging.  We have a “step-down” assessment 
battery if a participant is not able to tolerate the full outcome assessments.   
Accomplishment of the feasibility and efficacy aims of our proposed MINDSpeed pilot trial will support the 
development of a later stage ADRD prevention trial.  Such a trial would be scalable through the study 
applications described here, and likely would require multiple study sites.  These, we imagine, would come 
through the nation’s network of safety-net health systems referred to as America’s Essential Hospitals.  
The Essential Hospitals Institute is the research arm of the network and includes a mission to better 
understand upstream effects in efforts to improve population health in the communities served by members of 
America’s Essential Hospitals.  There are dozens of network sites around the nation, including sites that are 
also members of the Food as Medicine network, from which to draw upon and engage for an ADRD 
prevention trial, should our aims show promise. 
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Figure 1. Study Design 
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